No Definite Link Between Yoga, Quality of Life in Patients With Colorectal Cancer
the Cancer Therapy Advisor take:
Given the trial’s high attrition rate and low intervention adherence, no definite conclusions can be made between yoga and the health-related quality of life in patients with colorectal cancer, according to an article published online in the journal Psycho-Oncology.
Participants in this study included 54 patients (mean age 68.3 ± 9.7 years) who were randomly assigned to a 10-week yoga intervention (90 minutes once weekly; mean attendance 5.3 ± 4.0 yoga classes) or a waitlist control group. Twenty-seven patients were randomized to both the yoga and control group (attrition rate 22.2% and 18.5%, respectively).
Results showed no significant differences in the Functional Assessment of Cancer Therapy—Colorectal (FACT-C) total score between the two groups, which measured disease-specific quality of life.
However, differences were observed between the two groups’ emotional well-being at week 22 (∆ = 1.59; 95% CI: 0.27, 2.90; P= 0.019), sleep disturbances at week 22 (∆ = −1.08; 95% CI: −2.13, −0.03; P=0.043), anxiety at week 10 (∆ = −1.14; 95% CI: −2.20, −0.09; P=0.043), and depression at week 10 (∆ = −1.34; 95% CI: −2.61, −0.8; P=0.038).
Furthermore, no serious adverse events were observed in the yoga intervention cohort, while liver metastases occurred in one patient in the control group.
No definite conclusions can be made between yoga and the health-related quality of life in patients with colorectal cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Immunotherapy in Glioblastoma: Peaks and Pits
- Opinion: Understanding the FDA's Take on Cannabidiol
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Polymorphism in HSD3B1 as a Potential Prognostic Biomarker in Prostate Cancer
- Opioid Use and Cancer
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk